Skip to main content

Table 2 Pulmonary function, exercise capacity and smoking history of subject groups

From: Inflammatory cytokine response to exercise in alpha-1-antitrypsin deficient COPD patients ‘on’ or ‘off’ augmentation therapy

 

AATD + AUGa

AATD-AUGb

AATD PFTnormc

non-AATD COPDd

Healthye

FVC (liters)

3.85 ± 0.42

2.88 ± 0.16c

4.27 ± 0.64e

2.80 ± 0.32c,e

3.96 ± 0.57d

FVC (% pred)

88 ± 6c

79 ± 5c

109 ± 6e

77 ± 8c,e

95 ± 6d

FEV1 (liters)

1.23 ± 0.25c,e

1.35 ± 0.22c,e

3.22 ± 0.47e

1.49 ± 0.11c,e

3.07 ± 0.35d

FEV1 (% pred)

35 ± 5c,e

47 ± 7c,e

107 ± 4e

54 ± 7c,e

93 ± 4d

FEV1/FVC

31 ± 3c,d,e

47 ± 7c,e

76 ± 7c,e

56 ± 4c,e

79 ± 2d

FEV1/FVC (% pred)

40 ± 4c,d,e

61 ± 10c,e

97 ± 2e

71 ± 6c,e

99 ± 3d

Bike (two-legs) exercise

     

Watts

62 ± 6c,e

46 ± 11c,e

176 ± 47d,e

70 ± 11c,e

126 ± 17d

VO2peak (L/min)

1.02 ± 0.11c,e

0.69 ± 0.13c,e

2.07 ± 0.51d

1.16 ± 0.12c,e

1.71 ± 0.25d

VO2peak (ml/kg/min)

12.6 ± 0.5c

9.5 ± 1.1c,e

26.9 ± 5.6d,e

14.9 ± 1.7c

20.3 ± 3.3

Knee extensor (single-leg) exercise

     

Watts

25 ± 3c

21 ± 7c

59 ± 23d,e

21 ± 3c

26 ± 1

Smoking history

     

Never

17%

0%

25%

0%

0%

Ex-smoker

83%

100%

75%

43%

100%

Current

0%

0%

0%

57%

0%

  1. Data are mean ± SE. AATD, alpha-1 antitrypsin deficient; AUG, augmentation therapy; PFTnorm, pulmonary function testing normal; AAT, alpha-1 antitrypsin; COPD, chronic obstructive pulmonary disease; FVC, forced vital capacity; FEV1, forced expiratory volume at 1 sec; VO2peak, peak oxygen consumption during exercise. Significance difference between group is denoted as follows, ‘c’ different compared to AATD PFTnorm,‘d’ different compared to COPD, ‘e’ different compared to Healthy. No differences with respect to AATD + AUG ‘a’ or AATD-AUG ‘b’ were found. In all cases, significance is p ≤ 0.05.